Pete Williams
- Department of Clinical Neuroscience
- Division of Eye and Vision
- Glaucoma – Pete Williams' research group
About me
I received my BSc. (Hons) (Biomedical Sciences – Neuroscience, 2009) and PhD (Visual Neuroscience and Molecular Biology, 2012) from Cardiff University. I trained with Prof. James Morgan and Prof. Marcela Votruba studying autosomal dominant optic atrophy (ADOA, an inherited childhood neuropathy driven by mutations in OPA1), in addition to Parkinson’s disease, Alzheimer’s disease, and glaucoma. Following a short collaborative period exploring retinal ganglion cell dendritic degeneration during early glaucoma pathogenesis I joined the laboratory of Prof. Simon John (HHMI/The Jackson Laboratory) as a postdoctoral fellow in 2012 focusing on the early mechanisms that influence retinal and optic nerve degeneration in glaucoma. In 2017 I received a faculty funded career position at Karolinska Institutet where I formally started my lab in 2018.
Current appointments:
2022 - Present: Ulla and Ingemar Dahlberg Professor in Vision Science, Dept. of Clinical Neuroscience, Karolinska Institutet
2019 - Present: Research Group Leader, St Erik Eye Hospital
2018 - Present: Research Group Leader - Glaucoma, Dept. of Clinical Neuroscience, Karolinska Institutet
Other appointments:
2022 - Present: Academic Coordinator for KI’s Collaborations with the United Kingdom
2021 - Present: Founder/CEO, Mim Neurosciences AB
Honorary appointments:2024 - Present: Honorary Researcher, Centre for Eye Research Australia, Melbourne, Australia2023 - Present: Honorary Professor, School of Optometry and Vision Sciences, Cardiff University, Wales, UK
Education:
BSc. (Hons) Biomedical Sciences - Neuroscience, School of Biosciences, Cardiff University, Wales, UK (2009)
PhD Vision Sciences (Visual Neuroscience and Molecular Biology), School of Optometry and Vision Sciences, Cardiff University, Wales, UK (2012)
Docent (Neuroscience), Karolinska Institutet (2021)
Awards:
- ARVO Foundation/Pfizer Ophthalmics Carl Camras Translational Research Award (2023)
- Alcon Research Institute Young Investigator Award (2021)
- Axel Hirsch Prize (2021)
- 2021 Shaffer Prize for Innovation (2021)
- Swedish Ophthalmologic Society Most Promising Researcher 2020 / SOE-lecturer 2020 (2019)
- Excellence in Neuroscience Research award (Karolinska Institutet) (2019)
- The Barbara and Joseph Cohen Young Investigator Award (2013)
- European Association for Vision and Eye Research Best Paper in Category (Genetics) (2011)
Research
- The Pete Williams Lab (petewilliamslab.com) uses the eye as a model of the central nervous system to elucidate early mechanisms of neurodegeneration. We utilize modern transcriptomic and molecular tools to delicately dissect pathways pertaining to early aging and neurodegenerative disease mechanisms and to identify potential therapeutic targets which we then test and verify in animal and cell models of neurodegeneration. We work with clinicians to develop novel protective strategies that will benefit human health, aging, and disease.
Glaucoma is a complex, multifactorial disease affecting an estimated 80 million people worldwide and is the leading cause of irreversible blindness. It is a significant health and economic burden at both individual and societal level. Age, genetics, and high intraocular pressure (IOP) are all considerable risk factors. Despite strategies to manage IOP, >40% of treated glaucoma patients will progress to blindness. Neuroprotective treatments for glaucoma are of great therapeutic need. The Pete Williams Lab is developing new neuroprotective treatments for glaucoma, from bench-to-bedside.
The overarching theme of the Pete Williams Lab is to explore how bioenergetic insufficiency drives neurodegeneration and to identify novel neuroprotective therapies based on these data.
Glaucoma is characterized by the progressive dysfunction and loss of retinal ganglion cells (RGCs). RGCs are the output neurons of the retina, the axons of which become the optic nerve before integrating with key visual centers in the brain. Axon and dendritic degeneration are core components of glaucomatous neurodegeneration. RGCs sit on a metabolic knife-edge during times of stress that may be exacerbated by aging, genetic risk, and elevated IOP. During these periods, the viability of RGCs is reliant on mitochondria and supportive glia to maintain homeostasis and bioenergetic needs. Emerging research suggests that a systemic vulnerability to mitochondrial and metabolic abnormalities exists in glaucoma patients. Genomic analysis has demonstrated increased mitochondrial DNA content and a spectrum of mitochondrial DNA mutations in glaucoma patients. These abnormalities are also present in leukocytes, suggesting a systemic susceptibility to metabolic defects. Such systemic susceptibility is expected to increase glaucoma susceptibility with age.
Only strategies to lower IOP have been translated to the clinic and these therapeutics do not treat the neurodegenerative component of glaucoma. Patient adherence is variable and too many patients are subject to surgical interventions because of progressive damage. In addition, many patients are refractory to pressure lowering treatments and progress to blindness despite low pressures. So far, search for a treatment that targets RGCs and arrests progression, has a low side effect profile, and is cost-effective has been unsuccessful. Neuroprotective treatments for glaucoma are of great therapeutic need. Our research explores how this bioenergetic insufficiency drives neurodegeneration and identifies novel neuroprotective therapies based on these findings.
Major Current Research Theme: Neuronal NAD+ metabolism
NAD supplementation protects from bioenergetic insufficiency in glaucoma. We have previously discovered metabolic dysfunction and mitochondrial abnormalities occurring prior to neurodegeneration in glaucoma (in glaucoma patients and animal models). A key finding of these studies identified that NAD (an essential REDOX cofactor and metabolite) declines in the retina in an age-dependent manner and renders RGCs susceptible to glaucoma-related stresses, driving neurodegeneration. Preventing NAD depletion via administration of nicotinamide (NAM, the amide of vitamin B₃, an NAD precursor) or through gene therapy (Nmnat1 or Nmnat2, terminal enzymes or NAD production) robustly protects from age-related neuronal metabolic decline and prevents glaucoma in chronic animal models. Supporting a hypothesis in which pathogenically low NAD leads to glaucoma susceptibility, glaucoma patients have been demonstrated to have systemically low levels of nicotinamide (in sera), and we, as part of a multi-national collaborative clinical trial, have demonstrated that nicotinamide administration can restore visual function in existing glaucoma patients. Our continued work with nicotinamide exemplifies the lab’s commitment to developing translational neuroprotective strategies, from bench-to-bedside.
Ongoing Research Themes:
Mitochondria
We use a variety of novel reporter mice, mitochondrial markers, and live/vital dyes to image and analyze mitochondria at ultra-high resolution in healthy, disease, and treated states.
Neuronal Metabolism
We use targeted assays, targeted and enriched mass. spec. protocols, and high resolution untargeted metabolomics to identify novel disease pathways and candidate biomarkers in glaucoma.
Gene Therapies
Viral gene therapy has been successful in a handful of rare, monogenic ophthalmic diseases. We are expanding this work to develop gene therapies targeting common neurodegenerative pathways.
Neuroinflammation
Neuroinflammation within the retina and optic nerve may be a critical pathogenic event in early glaucoma. Our research explores microglia activation throughout the visual system in glaucoma.
Articles
- Article: REDOX BIOLOGY. 2025;85:103732Jonk SM; Nicol A; Chrysostomou V; Lardner E; Yu S-C; Stalhammar G; Crowston JG; Tribble JR; Swoboda P; Williams PA
- Article: MOLECULAR BRAIN. 2025;18(1):54Mouhammad ZA; Rombaut A; Bermudez MYG; Vohra R; Tribble JR; Williams PA; Kolko M
- Article: NEUROBIOLOGY OF AGING. 2025;150:69-79Bell KC; Chrysostomou V; Karlsson M; Jones BW; Williams PA; Crowston JG
- Article: CELL REPORTS MEDICINE. 2025;6(5):102127Tribble JR; Wong VHY; Stuart KV; Chidlow G; Nicol A; Rombaut A; Rabiolo A; Hoang A; Lee PY; Rutigliani C; Enz TJ; Canovai A; Lardner E; Stalhammar G; Nguyen CTO; Garway-Heath DF; Casson RJ; Khawaja AP; Bui BV; Williams PA
- Article: TRANSLATIONAL VISION SCIENCE & TECHNOLOGY. 2025;14(5):5Muth DR; Querat L; Venkataraman AP; Dominguez-Vicent A; Petrovski G; Williams PA; Locri F; Zweifel SA; Kvanta A
- Journal article: NEURAL REGENERATION RESEARCH. 2025;20(1):41-53Canovai A; Williams PA
- Article: MOLECULAR BRAIN. 2024;17(1):84Rombaut A; Brautaset R; Williams PA; Tribble JR
- Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2024;65(12):4Hedstrom J; Nilsson M; Engvall M; Williams PA; Venkataraman AP
- Journal article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2024;12(1):137Cimaglia G; Tribble JR; Votruba M; Williams PA; Morgan JE
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2024;12(1):137Cimaglia G; Tribble JR; Votruba M; Williams PA; Morgan JE
- Article: NATURE MEDICINE. 2024;30(8):2362-2370Petriti B; Rabiolo A; Chau K-Y; Williams PA; Montesano G; Lascaratos G; Garway-Heath DF
- Article: NATURE COMMUNICATIONS. 2024;15(1):6256Tribble JR; Joee M; Varricchio C; Otmani A; Canovai A; Habchi B; Daskalakis E; Chaleckis R; Loreto A; Gilley J; Wheelock CE; Johannesson G; Wong RCB; Coleman MP; Brancale A; Williams PA
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2024;12(1):79Rombaut A; Jovancevic D; Wong RC-B; Nicol A; Brautaset R; Finkelstein DI; Nguyen CTO; Tribble JR; Williams PA
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2024;12(1):65Kim M; Kim JY; Rhim W-K; Cimaglia G; Want A; Morgan JE; Williams PA; Park CG; Han DK; Rho S
- Article: BMC NEUROLOGY. 2024;24(1):111Svensson JE; Bolin M; Thor D; Williams PA; Brautaset R; Carlsson M; Sorensson P; Marlevi D; Spin-Neto R; Probst M; Hagman G; Moren AF; Kivipelto M; Plaven-Sigray P
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2024;12(1):37Otmani A; Johannesson G; Brautaset R; Tribble JR; Williams PA
- Journal article: ACTA OPHTHALMOLOGICA. 2024;102(S279)Mouhammad ZA; von Spreckelsen A; Bermudez MYG; Vohra R; Williams P; Kolko M
- Journal article: ACTA OPHTHALMOLOGICA. 2024;102(S279)Tribble JR; Rutigliani C; Canovai A; Williams PA
- Article: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(14):34Gustavsson ST; Enz TJ; Tribble JR; Nilsson M; Lindqvist A; Linden C; Hagstrom A; Rutigliani C; Lardner E; Stalhammar G; Williams PA; Johannesson G
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2023;11(1):146Canovai A; Tribble JR; Joe M; Westerlund DY; Amato R; Trounce IA; Dal Monte M; Williams PA
- Article: GENE THERAPY. 2023;30(6):503-519Nieuwenhuis B; Laperrousaz E; Tribble JR; Verhaagen J; Fawcett JW; Martin KR; Williams PA; Osborne A
- Article: BMC CANCER. 2023;23(1):277Herrspiegel C; Plastino F; Lardner E; Seregard S; Williams PA; Andre H; Stalhammar G
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2023;11(1):18Tribble JR; Hagstrom A; Jusseaume K; Lardner E; Wong RC-B; Stalhammar G; Williams PA
- Article: JOURNAL OF BIOPHOTONICS. 2022;15(12):e202200169Enz TJ; Maloca PM; Tschopp M; Menke MN; Tribble JR; Williams PA; Inglin N; Steitz U; Scholl HPN; Papazoglou A
- Article: DISCOVER ONCOLOGY. 2022;13(1):116Stalhammar G; Williams PA; Landelius T
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2022;10(1):118Rutigliani C; Tribble JR; Hagstrom A; Lardner E; Johannesson G; Stalhammar G; Williams PA
- Article: FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY. 2022;10:903436Tribble JR; Kastanaki E; Uslular AB; Rutigliani C; Enz TJ; Williams PA
- Article: TRANSLATIONAL VISION SCIENCE & TECHNOLOGY. 2022;11(2):1-13Enz TJ; Bittner M; Tribble JR; Williams PA; Thiel MA; Schmid MK; Bachmann LM; Bochmann F
- Article: JAMA OPHTHALMOLOGY. 2022;140(1):11-18De Moraes CG; John SWM; Williams PA; Blumberg DM; Cioffi GA; Liebmann JM
- Article: JOURNAL OF CLINICAL MEDICINE. 2021;10(17):3938Enz TJ; Tribble JR; Williams PA
- Article: REDOX BIOLOGY. 2021;43:101988Tribble JR; Otmani A; Sun S; Ellis SA; Cimaglia G; Vohra R; Joe M; Lardner E; Venkataraman AP; Dominguez-Vicent A; Kokkali E; Rho S; Johnnesson G; Burgess RW; Fuerst PG; Brautaset R; Kolko M; Morgan JE; Crowston JG; Votruba M; Williams PA
- Article: TRANSLATIONAL VISION SCIENCE & TECHNOLOGY. 2021;10(1):22Tribble JR; Kokkali E; Otmani A; Plastino F; Lardner E; Vohra R; Kolko M; Andre H; Morgan JE; Williams PA
- Article: TRANSLATIONAL VISION SCIENCE & TECHNOLOGY. 2021;10(1):21Tribble JR; Otmani A; Kokkali E; Lardner E; Morgan JE; Williams PA
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2020;117(52):33619-33627Harder JM; Guymer C; Wood JPM; Daskalaki E; Chidlow G; Zhang C; Balasubramanian R; Cardozo BH; Foxworth NE; Deering KE; Ouellette TB; Montgomery C; Wheelock CE; Casson RJ; Williams PA; John SWM
- Article: ACTA NEUROPATHOLOGICA COMMUNICATIONS. 2020;8(1):216Bevan RJ; Hughes TR; Williams PA; Good MA; Morgan BP; Morgan JE
- Article: JOURNAL OF NEUROINFLAMMATION. 2020;17(1):336Harder JM; Williams PA; Braine CE; Yang HS; Thomas JM; Foxworth NE; John SWM; Howell GR
- Article: NATURE COMMUNICATIONS. 2020;11(1):5614Petrova V; Pearson CS; Ching J; Tribble JR; Solano AG; Yang Y; Love FM; Watt RJ; Osborne A; Reid E; Williams PA; Martin KR; Geller HM; Eva R; Fawcett JW
- Article: CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY. 2020;48(7):903-914Hui F; Tang J; Williams PA; McGuinness MB; Hadoux X; Casson RJ; Coote M; Trounce IA; Martin KR; van Wijngaarden P; Crowston JG
- Article: BRAIN COMMUNICATIONS. 2020;2(2):fcaa101Bevan RJ; Williams PA; Waters CT; Thirgood R; Mui A; Seto S; Good M; Morgan JE; Votruba M; Erchova I
- Article: MOLECULAR BRAIN. 2020;13(1):81Tribble J; Harder JM; Williams P; John SWM
- Article: MOLECULAR NEURODEGENERATION. 2019;14(1):6Williams PA; Braine CE; Kizhatil K; Foxworth NE; Tolman NG; Harder JM; Scott RA; Sousa GL; Panitch A; Howell GR; John SWM
- Article: BRAIN COMMUNICATIONS. 2019;1(1):fcz035Tribble JR; Vasalauskaite A; Redmond T; Young RD; Hassan S; Fautsch MP; Sengpiel F; Williams PA; Morgan JE
- Article: MOLECULAR BRAIN. 2018;11(1):69Tribble JR; Williams PA; Caterson B; Sengpiel F; Morgan JE
- Article: CELL DEATH & DISEASE. 2018;9(6):705Harder JM; Williams PA; Soto I; Foxworth NE; Fernandes KA; Freeburg NF; Libby RT; John SWM
- Article: NATURE COMMUNICATIONS. 2018;9(1):2278Choquet H; Paylakhi S; Kneeland SC; Thai KK; Hoffmann TJ; Yin J; Kvale MN; Banda Y; Tolman NG; Williams PA; Schaefer C; Melles RB; Risch N; John SWM; Nair KS; Jorgenson E
- Article: COMMUNICATIVE AND INTEGRATIVE BIOLOGY. 2018;11(1):e1356956Williams PA; Harder JM; Cardozo BH; Foxworth NE; John SWM
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2017;114(19):E3839-E3848Harder JM; Braine CE; Williams PA; Zhu X; MacNicoll KH; Sousa GL; Buchanan RA; Smith RS; Libby RT; Howell GR; John SWM
- Article: JOURNAL OF NEUROINFLAMMATION. 2017;14(1):93Williams PA; Braine CE; Foxworth NE; Cochran KE; John SWM
- Article: FRONTIERS IN NEUROSCIENCE. 2017;11:232Williams PA; Harder JM; Foxworth NE; Cardozo BH; Cochran KE; John SWM
- Article: EXPERIMENTAL EYE RESEARCH. 2017;157:20-27Williams PA; Marsh-Armstrong N; Howell GR
- Article: SCIENCE. 2017;355(6326):756-760Williams PA; Harder JM; Foxworth NE; Cochran KE; Philip VM; Porciatti V; Smithies O; John SWM
- Article: MOLECULAR NEURODEGENERATION. 2016;11:26Williams PA; Tribble JR; Pepper KW; Cross SD; Morgan BP; Morgan JE; John SWM; Howell GR
- Article: EXPERIMENTAL EYE RESEARCH. 2015;141:42-56Fernandes KA; Harder JM; Williams PA; Rausch RL; Kiernan AE; Nair KS; Anderson MG; John SWM; Howell GR; Libby RT
- Article: IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING. 2015;23(4):655-664Lee ST; Williams PA; Braine CE; Lin D-T; John SWM; Irazoqui PP
- Article: PLOS ONE. 2013;8(8):e72282Williams PA; Howell GR; Barbay JM; Braine CE; Sousa GL; John SWM; Morgan JE
- Article: NEUROBIOLOGY OF AGING. 2013;34(7):1799-1806Williams PA; Thirgood RA; Oliphant H; Frizzati A; Littlewood E; Votruba M; Good MA; Williams J; Morgan JE
- Article: BRAIN. 2012;135(Pt 2):493-505Williams PA; Piechota M; von Ruhland C; Taylor E; Morgan JE; Votruba M
- Article: EXPERIMENTAL EYE RESEARCH. 2011;93(5):771-777Barnard AR; Issa PC; Perganta G; Williams PA; Davies VJ; Sekaran S; Votruba M; MacLaren RE
- Article: BRAIN. 2010;133(10):2942-2951Williams PA; Morgan JE; Votruba M
- Show more
All other publications
- Editorial comment: NEURAL REGENERATION RESEARCH. 2026;21(2):693-694Joe M; Williams PA
- Review: BRAIN RESEARCH BULLETIN. 2025;229:111437Jonk SM; Tribble JR; Swoboda P; Williams PA
- Review: BMJ OPEN OPHTHALMOLOGY. 2025;10(1):e002103Golpour N; Brautaset RL; Hui F; Nilsson M; Svensson JE; Williams PA; Tribble JR
- Book chapter: ENCYCLOPEDIA OF THE EYE. 2025;p. 92-104Williams PA; Hui F
- Review: NEURAL REGENERATION RESEARCH. 2025;20(1):41-53Canovai A; Williams PA
- Review: SURVEY OF OPHTHALMOLOGY. 2025;70(1):38-46Stalhammar G; Hagstrom A; Conradi ME; Williams PA
- Corrigendum: NATURE COMMUNICATIONS. 2024;15(1):8143Tribble JR; Joee M; Varricchio C; Otmani A; Canovai A; Habchi B; Daskalakis E; Chaleckis R; Loreto A; Gilley J; Wheelock CE; Johannesson G; Wong RCB; Coleman MP; Brancale A; Williams PA
- Editorial comment: NEURAL REGENERATION RESEARCH. 2024;19(8):1637-1638Williams PA; Casson RJ
- Preprint: MEDRXIV. 2024Svensson J; Bolin M; Thor D; Williams P; Brautaset R; Carlsson M; Sörensson P; Marlevi D; Spin-Neto R; Probst M; Hagman G; Morén AF; Kivipelto M; Plavén-Sigray P
- Review: FRONTIERS IN OPHTHALMOLOGY. 2023;3:1290465Rombaut A; Brautaset R; Williams PA; Tribble JR
- Preprint: RESEARCH SQUARE. 2023Petriti B; Rabiolo A; Chau K-Y; Williams P; Montesano G; Lascaratos G; Garway-Heath D
- Review: MOLECULAR NEURODEGENERATION. 2023;18(1):64Soucy JR; Aguzzi EA; Cho J; Gilhooley MJ; Keuthan C; Luo Z; Monavarfeshani A; Saleem MA; Wang X-W; Wohlschlegel J; Baranov P; Di Polo A; Fortune B; Gokoffski KK; Goldberg JL; Guido W; Kolodkin AL; Mason CA; Ou Y; Reh TA; Ross AG; Samuels BC; Welsbie D; Zack DJ; Johnson TV
- Review: MOLECULAR ASPECTS OF MEDICINE. 2023;92:101193Tribble JR; Hui F; Quintero H; El Hajji S; Bell K; Di Polo A; Williams PA
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(8)Halsmer EL; DeQuattro C; Wang S; Harman C; Anderson A; Williams P; Komaromy AM
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(8)Petriti B; Rabiolo A; Williams P; Chau K-Y; Lascaratos G; Garway-Heath DF
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(8)Williams P; Tribble JR; Joe M; Brancale A; Varricchio C; Coleman M; Gilley J; Loreto A; Wheelock C; Johannesson G
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(8)Joe M; Tribble JR; Varricchio C; Brancale A; Johannesson G; Wheelock C; Williams P
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(8)Williams P
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2023;64(8)Komaromy A; Harman C; Anderson A; Williams P
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2022;63(7)Tribble JR; Kastanaki E; Uslular AB; Rutigliani C; Enz TJ; Williams PA
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2022;63(7)Williams PA; Tribble JR; Joe M; Brancale A; Varricchio C; Coleman M; Gilley J; Loreto A; Wheelock C; Johannesson G
- Review: BMC CANCER. 2022;22(1):398Hagstrom A; Kal Omar R; Williams PA; Stalhammar G
- Review: FRONTIERS IN NEUROSCIENCE. 2022;16:824054Mouhammad ZA; Vohra R; Horwitz A; Thein A-S; Rovelt J; Cvenkel B; Williams PA; Azuara-Blanco A; Kolko M
- Preprint: RESEARCH SQUARE. 2022Hagström A; Omar RK; Williams P; Stålhammar G
- Review: CELLS. 2021;10(6):1402Petriti B; Williams PA; Lascaratos G; Chau K-Y; Garway-Heath DF
- Review: PROGRESS IN RETINAL AND EYE RESEARCH. 2021;81:100881Casson RJ; Chidlow G; Crowston JG; Williams PA; Wood JPM
- Review: CELLS. 2021;10(2):295Tribble JR; Hui F; Joe M; Bell K; Chrysostomou V; Crowston JG; Williams PA
- Preprint: BIORXIV. 2020Tribble J; Otmani A; Sun S; Ellis S; Cimaglia G; Vohra R; Jöe M; Lardner E; Venkataraman A; Domínguez-Vicent A; Kokkali E; Rho S; Jóhannesson G; Burgess R; Fuerst P; Brautaset R; Kolko M; Morgan J; Crowston J; Votruba M; Williams P
- Review: NUTRIENTS. 2020;12(9):E2871-2871Cimaglia G; Votruba M; Morgan JE; Andre H; Williams PA
- Preprint: BIORXIV. 2020Yousefi S; Chen H; Ingels J; McCarty M; Centeno A; Chintalapudi S; Mulligan M; Williams P; John S; Jones B; Jablonski M; Hollingsworth TJ; Geisert E; Lu L; Williams R
- Preprint: RESEARCH SQUARE. 2020Harder JM; Williams P; Braine C; Yang H; Thomas J; Foxworth N; John S; Howell G
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2020;61(7)Hui F; Tang J; Williams P; McGuinness M; Hadoux X; Casson RJ; Coote M; Trounce I; Martin KR; van Wijngaarden P; Crowston JG
- Preprint: BIORXIV. 2020Williams P; Harder J; Guymer C; Wood J; Daskalaki E; Chidlow G; Cardozo B; Foxworth N; Cochran K; Ouellette T; Wheelock C; Casson R; John S
- Preprint: MEDRXIV. 2020Hui F; Tang J; Williams P; McGuinness M; Hadoux X; Casson R; Coote M; Trounce I; Martin K; van Wijngaarden P; Crowston J
- Preprint: BIORXIV. 2020Petrova V; Pearson C; Tribble J; Solano A; Reid E; Williams P; Geller H; Eva R; Fawcett J
- Preprint: BIORXIV. 2019Tribble J; Harder J; Williams P; John S
- Preprint: BIORXIV. 2019Tribble J; Kokkali E; Otmani A; Plastino F; Lardner E; Vohra R; Kolko M; André H; Morgan J; Williams P
- Review: JOURNAL OF GLAUCOMA. 2017;26(12):1161-1168Williams PA; Harder JM; John SWM
- Conference publication: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. 2016;57(12)Howell GR; Williams P; Harder J; Tribble J; Pepper K; Cross S; Morgan P; Morgan JE; John SW
- Published conference paper: VISION RESEARCH. 2011;51(2):229-234Williams PA; Morgan JE; Votruba M
- Show more
Grants
- Targeting NAD metabolism for neuroprotection in age-related ophthalmic and neurodegenerative diseaseSwedish Research Council1 January 2023 - 31 December 20262.2 billion people live with visual impairment and blindness worldwide. Only ~50% of these cases are directly preventable which highlights the need to further develop and advance treatments for ophthalmic diseases. Even within nations with developed and accessible healthcare systems visual impairments are prevalentespecially from ocular neurodegenerations which are compounded by an ever-increasing aged global population. There is a pressing need to address these diseases and to develop new diagnostic techniques and new therapeutic avenues.The goal of this VR research program is to develop clinically translatable neuroprotective strategies for glaucoma and other age-related ophthalmic neurodegenerative diseases by focusing on NAD metabolism. My team will use –omics technologies, super-resolution imaging, animal and human clinical samples, and novel pharmacology to develop clinically translational neuroprotective strategies.Specifically, this program will:Target NAD-metabolism to develop new long-term neuroprotective strategies based on gene therapy and small molecule pharmacology, and,Test their specificity utilizing mammalian and nematode genetics,Assess metabolic disruption in glaucoma patient samples and in treated patients to identify additional routes to neuroprotection.The combination of these themes will identify the molecular underpinnings of neurodegeneration in glaucoma and lead to novel therapeutic strategies for age-related ophthalmic neurodegenerative disease.
- Swedish Research Council1 January 2019 - 31 December 2022
Employments
- Professor, Department of Clinical Neuroscience, Karolinska Institutet, 2025-
- Senior Lecturer, Department of Clinical Neuroscience, Karolinska Institutet, 2022-2025
Degrees and Education
- Docent, Karolinska Institutet, 2021